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The transient receptor potential vanilloid 1 (TRPV1) is a non-selective ligand-gated
cation channel involved in synaptic transmission, plasticity, and brain pathology. In
the hippocampal dentate gyrus, TRPV1 localizes to dendritic spines and dendrites
postsynaptic to excitatory synapses in the molecular layer (ML). At these same synapses,
the cannabinoid CB1 receptor (CB1R) activated by exogenous and endogenous
cannabinoids localizes to the presynaptic terminals. Hence, as both receptors are
activated by endogenous anandamide, co-localize, and mediate long-term depression
of the excitatory synaptic transmission at the medial perforant path (MPP) excitatory
synapses though by different mechanisms, it is plausible that they might be exerting
a reciprocal influence from their opposite synaptic sites. In this anatomical scenario,
we tested whether the absence of TRPV1 affects the endocannabinoid system. The
results obtained using biochemical techniques and immunoelectron microscopy in a
mouse with the genetic deletion of TRPV1 show that the expression and localization
of components of the endocannabinoid system, included CB1R, change upon the
constitutive absence of TRPV1. Thus, the expression of fatty acid amide hydrolase
(FAAH) and monoacylglycerol lipase (MAGL) drastically increased in TRPV1−/− whole
homogenates. Furthermore, CB1R and MAGL decreased and the cannabinoid receptor
interacting protein 1a (CRIP1a) increased in TRPV1−/− synaptosomes. Also, CB1R
positive excitatory terminals increased, the number of excitatory terminals decreased,
and CB1R particles dropped significantly in inhibitory terminals in the dentate ML of
TRPV1−/− mice. In the outer 2/3ML of the TRPV1−/− mutants, the proportion of CB1R
particles decreased in dendrites, and increased in excitatory terminals and astrocytes.
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In the inner 1/3ML, the proportion of labeling increased in excitatory terminals, neuronal
mitochondria, and dendrites. Altogether, these observations indicate the existence of
compensatory changes in the endocannabinoid system upon TRPV1 removal, and
endorse the importance of the potential functional adaptations derived from the lack
of TRPV1 in the mouse brain.
Keywords: endovanilloid, endocannabinoid enzymes, dentate gyrus, immunoelectron microscopy, cannabinoid
(CB) receptor 1
INTRODUCTION
The endocannabinod system (ECS) made up of cannabinoid
receptors (CB1R, CB2R, among others), the main
endocannabinoids, 2-arachydonoyl-glycerol (2-AG) and
anandamide (AEA), the main synthesizing enzymes for
2-AG (diacylglycerol lipase, DAGL) and AEA (N-acyl
phosphatidylethanolamine phospholipase D, NAPE-PLD),
and their main degrading enzymes (2-AG: monoacylglycerol
lipase, MAGL; AEA: fatty acid amide hydrolase, FAAH) as well
as transport proteins, plays an essential role in hippocampal
synaptic plasticity (Kano et al., 2009; Castillo et al., 2012;
Maccarrone, 2017; Monday et al., 2020). Although the main
enzymes for synthesis and degradation of 2-AG and AEA are
selectively segregated at either presynaptic or postsynaptic sites
(Gulyas et al., 2004; Katona et al., 2006; Yoshida et al., 2006;
Blankman et al., 2007; Lafourcade et al., 2007; Starowicz et al.,
2007; Puente et al., 2011; Reguero et al., 2011; Suárez et al.,
2011) redundant pathways for 2-AG and AEA turnover also
exit (for review, see Murataeva et al., 2014). Endocannabinoids
regulate synaptic function at both excitatory and inhibitory
synapses by retrograde signaling (Kano et al., 2009; Castillo
et al., 2012) and also through astrocytes (Navarrete and Araque,
2008, 2010; Han et al., 2012). The CB1R is highly localized
to inhibitory GABAergic synaptic terminals and preterminals
(Kawamura et al., 2006; Katona and Freund, 2012; Steindel et al.,
2013; Shu-Jung Hu and Mackie, 2015; Gutiérrez-Rodríguez
et al., 2017), in contrast to its limited presence at excitatory
glutamatergic terminals (Marsicano et al., 2003; Monory et al.,
2006; Puente et al., 2011; Ruehle et al., 2013; Gutiérrez-Rodríguez
et al., 2017), astrocytes (Stella, 2010; Han et al., 2012; Metna-
Laurent and Marsicano, 2015; Gutiérrez-Rodríguez et al., 2018),
and neuronal and astroglial mitochondria (Bénard et al., 2012;
Hebert-Chatelain et al., 2014a,b; Gutiérrez-Rodríguez et al., 2018;
Jimenez-Blasco et al., 2020). AEA and 2-AG also activate TRPV1
(Zygmunt et al., 1999, 2013; De Petrocellis et al., 2017; Muller
et al., 2019) which regulates synaptic transmission and signals
pain in the peripheral nervous system (Caterina et al., 2000). It
is also in many cells and regions of the central nervous system
(Tóth et al., 2005; Cristino et al., 2006) despite the observation
of low TRPV1 expression in reporter mouse brain (Cavanaugh
et al., 2011). Nonetheless, TRPV1 participates in hefty brain
functions, e.g., excitatory and inhibitory synaptic transmission
and plasticity, learning and memory, cortical excitability, or fear
and anxiety (Marsch et al., 2007; Chávez et al., 2010; Chavez
et al., 2014; Puente et al., 2011; Hurtado-Zavala et al., 2017;
Bialecki et al., 2020), intervenes in brain neurogenesis, regulates
neural proliferation/differentiation rate (Ramírez-Barrantes
et al., 2016) and contributes to AEA transport into endothelial
cells (Hofmann et al., 2014).
The use of immunoelectron microscopy has revealed
localizations from where TRPV1 regulates neural activity.
Thus, TRPV1 localized presynaptically to excitatory synaptic
terminals in the CA1 hippocampus facilitates AEA-mediated
glutamate release (Bialecki et al., 2020). Also, TRPV1 localized
postsynaptically to both, inhibitory synapses in the inner 1/3
of the dentate ML (Canduela et al., 2015) regulates GABAergic
synaptic transmission (Chavez et al., 2014), and to excitatory
synapses in the outer 2/3 of the ML (Puente et al., 2015) where
AEA triggers TRPV1-dependent and CB1R-independent long-
term depression of the excitatory synaptic transmission (eLTD)
at the MPP synapses (Chávez et al., 2010). Interestingly, at
these same excitatory synapses, MPP stimulation (10Hz, 10min)
triggered a group I metabotropic glutamate receptor-dependent
and CB1R-mediated eLTD that required intracellular calcium
and 2-AG synthesis (Peñasco et al., 2019). So, the question
raises as whether both receptors would influence each other by
acting from opposite loci of the same synapse. In this sense,
the existence of interactions between both the endocannabinoid
and endovanilloid system has been suggested (Starowicz et al.,
2007). AEA increase reduces 2-AG effect on presynaptic CB1Rs
through postsynaptic TRPV1 resulting in short-term plasticity
regulation (Maccarrone et al., 2008; Musella et al., 2010; Lee et al.,
2015). Genetic deletion of endocannabinoid system components
leads to compensatory changes in TRPV1; for instance, TRPV1
expression decreases in dentate gyrus and increases in the
cerebellar granule cell layer in mice lacking CB1R (Cristino
et al., 2006). Also, CB1R and TRPV1 expressed in the same cell
mediate opposite effects on intracellular calcium levels (Szallasi
and Di Marzo, 2000), glutamate release (Marinelli et al., 2003)
or excitatory and inhibitory neurotransmission (Tahmasebi et al.,
2015). Altogether, these previous findings endorse reciprocal and
complex bidirectional interactions between CB1R and TRPV1
expressed at the same synapse (Zádor and Wollemann, 2015).
We sought in this study compensatory mechanisms in the
endocannabinoid system in a mouse model carrying the genetic
deletion of TRPV1 (TRPV1−/−), which might eventually have
an impact on neural information processing. Hence, biochemical
and immunohistochemical tools were used to explore the
overall expression patterns of some key endocannabinoid
system components (DAGL, MAGL, NAPE-PLD, FAAH). Also,
immunoelectron microscopy was applied to assess CB1R
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rearrangements in the TRPV1−/− hippocampal dentate gyrus
where both receptors are involved in mechanistically distinct
eLTD at the MPP synapses (Chávez et al., 2010; Peñasco et al.,
2019). The results show that the expression and localization of
some components of the endocannabinoid system change upon
the constitutive absence of TRPV1.
MATERIALS AND METHODS
Animal Procedures
All protocols were approved by the Committee of Ethics for
Animal Welfare of the University of the Basque Country
(CEEA/M20/2015/105; CEIAB/M30/2015/106) and were in
accordance to the European Communities Council Directive
of 22nd September 2010 (2010/63/EU) and Spanish regulations
(Real Decreto 53/2013, BOE 08-02-2013). All efforts were made
to minimize pain and suffering and to reduce the number of
animals used. Eight week-old-male TRPV1−/− mice and their
wild type (WT) littermates (TRPV1+/+) were used (n = 18
each). The TRPV1−/− mice (C57BL/6 J background; Caterina
et al., 2000) were derived from heterozygous breeding pairs
generated by crossing of B6.129X1-Trpv1tm1Jul/J mice (The
Jackson Laboratory, Bar Harbor, ME) with C57BL/6 j mice
(Janvier Labs) at the General Animal Unit Service of the
University of the Basque Country (UPV/EHU). The mice used
were genotyped in the Genomics and Proteomics Unit of the
University of the Basque Country (UPV/EHU).
Mice were housed in pairs or groups of maximum three
littermates in standard Plexiglas cages (17 × 14.3 × 36.3 cm)
and before experiments were conducted, they were allowed to
acclimate to the environment for at least 1 week. They were
maintained at standard conditions with food and tap water ad
libitum throughout all experiments in a room with constant
temperature (22◦C), and kept in a 12:12 h light/dark cycle with
lights off at 9:00 p.m.
Tissue Preservation
The TRPV1−/− and WT mice were deeply anesthetized by
intraperitoneal administration of a mixture of ketamine/xilacine
(80/10 mg/kg body weight). They were transcardially perfused
at room temperature (RT) with phosphate buffered saline (0.1M
PBS, pH 7.4) for 20 s, followed by the iced-cooled fixative solution
made up of 4% formaldehyde (freshly depolymerized from
paraformaldehyde), 0.2% picric acid, and 0.1% glutaraldehyde
in 0.1M phosphate buffer (PB, pH 7.4) for 10–15min. Then,
brains were carefully removed from the skull and post-fixed in
the fixative solution for 1 week at 4◦C followed by their storage
in 1:10 fixative solution diluted in 0.1M PB with 0.025% sodium
azide at 4◦C until use.
Immunohistochemistry for Light
Microscopy
The procedure was published elsewhere (Gutiérrez-Rodríguez
et al., 2017). Briefly, 50 µm-thick brain coronal vibratome
sections were cut and collected in 0.1M PB at RT. Hippocampal
sections were preincubated in 10% horse normal serum (HNS),
0.1% sodium azide, and 0.5% Triton X-100 in Tris-HCl-buffered
saline (TBS) (pH 7.4) for 30min at RT, and then incubated with
one of the following primary polyclonal antibodies: goat anti-
CB1R (2µg/ml; Frontier Institute co., ltd; CB1-Go-Af450; RRID:
AB_2571591); rabbit anti-MAGL (2µg/ml; Frontier Institute co,
ltd; MGL-Rb-Af200; RRID: AB_2571798); rabbit anti-DAGLα
(2µg/ml; Frontier Institute co, ltd; DGLa-Rb-Af380; RRID:
AB_2571691); guinea pig anti-NAPE-PLD (4µg/ml; Frontier
Institute co, ltd; NAPE-PLD-Gp-Af720; RRID: AB_2571806) or
rabbit anti-FAAH (1µg/ml; Cayman Chemical; 101600-1; RRID:
AB_327842), on a shaker for 2 days at 4◦C. After several washes
in 1% HNS and 0.5% Triton X-100 in TBS, the respective
hippocampal samples were incubated with the corresponding
biotinylated horse anti-goat IgG (1:200; Cat# BA-9500; RRID:
AB_2336123; Vector Laboratories, Burlingame, CA), goat anti-
rabbit IgG (1:200; Cat# BA-1000; RRID: AB_2313606; Vector
Laboratories, Burlingame, CA), goat anti-guinea pig IgG
(1:200; Cat# bs-03586; RRID: AB_10860553; Bioss, USA) for
1 h on a shaker at RT, washed in the solution described
above and processed for the avidin-biotin peroxidase complex
method (ABC; 1:50; Elite; Cat#PK-6100, Vector Laboratories,
Burlingame, CA; RRID: AB_2336819). Hence, sections were
incubated in the avidin-biotin complex prepared in washing
solution (1:50) for 1 h at RT. Then, they were washed and
incubated with 0.05% diaminobenzidine (DAB) in 0.1M PB
with 0.5% Triton X-100 and 0.01% hydrogen peroxide, for
5min at RT. Finally, tissue was mounted, dehydrated in graded
alcohols (50, 70, 96, 100%) to xylol and coverslipped with
DPX. Sections were observed and photographed with a Zeiss
Axiophot light microscope. All micrographs were taken at the
same light intensity and exposure time. Adjustments in contrast
and brightness were made to the figures in Adobe Photoshop
(CS3, Adobe Systems; RRID: SCR_014199).
CB1R Immunoelectron Microscopy
The procedure has already been described in detail elsewhere
(Puente et al., 2019). Briefly, hippocampal sections were pre-
incubated in a blocking solution of 10%HNS, 0.1% sodium azide,
and 0.02% saponine prepared in TBS (pH 7.4) for 30min at
RT. Then hippocampal sections were incubated with a goat anti-
CB1R antibody (2µg/ml, #CB1-Go-Af450, Frontier Science Co.;
RRID: AB_257130) in 10% HNS/TBS containing 0.1% sodium
azide and 0.004% saponine on a shaker for 2 days at 4◦C. After
several washes in 1% HNS/TBS, tissue sections were incubated
with a 1.4 nm gold-labeled rabbit anti-goat IgG (Fab’ fragment,
1:100, Nanoprobes Inc., Yaphank, NY, USA Cat#2004; RRID:
AB_2631182) in 1% HNS/TBS with 0.004% saponine on a shaker
for 4 h at RT. Thereafter, hippocampal sections were washed in
1%HNS/TBS overnight at 4◦C, postfixed in 1% glutaraldehyde in
TBS for 10min and washed in double-distilled water. Then, gold
particles were silver-intensified with a HQ Silver kit (Nanoprobes
Inc., Yaphank, NY, USA; Cat#2012) for ∼12min in the dark
and washed in 0.1M PB. Stained sections were osmicated (1%
OsO4 (v/v) in 0.1M PB, 20min; Electron Microscopy Sciences;
Cat#19150), dehydrated in graded alcohols to propylene oxide
and plastic-embedded in Epon resin 812. Ultrathin sections (50
nm-thick) were collected on nickel mesh grids, stained with 2.5%
lead citrate for 20min and examined in an electron microscope
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(Philips EM208S). Tissue preparations were photographed by
using a digital camera (Digital Morada Camera, Olympus)
coupled to the electron microscope. Adjustments in contrast and
brightness were made to the figures using Adobe Photoshop
(CS3, Adobe Systems; RRID: SCR_014199).
Double CB1R and Glial Fibrillary Acidic
Protein (GFAP) Immunoelectron
Microscopy
Co-labeling experiments were performed as described (Puente
et al., 2019). The first steps were shared with the single
pre-embedding immunogold method. Then, the hippocampal
sections were simultaneously incubated with the goat anti-
CB1R antibody (2µg/ml, #CB1-Go-Af450, Frontier Science Co.;
RRID: AB_257130) and a mouse anti-GFAP antibody (20 ng/ml;
G3893; Sigma-Aldrich, mouse monoclonal; RRID: AB_257130)
in 10% HNS/TBS with 0.1% sodium azide and 0.004% saponin
on a shaker for 2 days at 4◦C. After several washes in 1%
HNS/TBS, tissue sections were incubated with both 1.4 nm gold-
labeled rabbit anti-goat IgG (Fab’ fragment, 1:100, Nanoprobes
Inc., Yaphank, NY, USA) for the localization of CB1R and a
biotinylated horse anti-mouse IgG (1:200 Vector Labs, Cat#BA-
2000; RRID: AB_2313581) for the localization of GFAP, diluted
in 1% HNS/TBS with 0.004% saponin on a shaker for 4 h at
RT. Then, sections were incubated in avidin-biotin peroxidase
complex (ABC) prepared in 1% HNS/TBS for 1.5 h at RT. They
were subsequently washed in 1% HNS/TBS overnight at 4◦C
and postfixed in 1% glutaraldehyde in TBS for 10min at RT.
Following several washes in double-distilled water, gold particles
were silver intensified with an HQ Silver kit (Nanoprobes Inc.,
Cat#2012) for ∼12min in the dark and washed in 0.1M PB,
pH 7.4. Then, the tissue was incubated in 0.05% DAB (Sigma-
Aldrich, Cat#D5637; RRID: AB_2336819) and 0.01% hydrogen
peroxide prepared in 0.1M PB for 3min. Labeled sections were
osmicated (1% osmium tetroxide, Electron Microscopy Sciences,
Cat#19150) in 0.1M PB, pH 7.4, 20min, dehydrated in graded
alcohols to propylene oxide, and plastic-embedded in Epon
resin 812. Ultrathin sections (50 nm-thick) were collected on
nickel mesh grids, counterstained with 2.5% lead citrate for
20min and examined with an electron microscope (JEOL JEM
1400 Plus). Tissue samples were imaged using a digital camera
(sCMOS). Figures were created with Adobe Photoshop (CS3,
Adobe Systems; RRID: SCR_014199).
Semi-quantification Analysis
Hippocampal sections from TRPV1−/− (n = 3) and WT mice
(n = 3) were visualized under a light microscope in order to
select portions of the inner 1/3 (hilar mossy cell axon terminal
synapses) and outer 2/3 of the dentate ML (perforant path
synapses) with good, reproducible immunolabeling and well-
preserved ultrastructure. All electron micrographs were taken
at ×22,000 magnification and showed similar labeling intensity,
indicating that the selected areas were at the same depth.
Furthermore, only ultrathin sections within the first 1.5µm from
the surface of the tissue block were examined to avoid false
negatives. Metal particles placed on membranes were counted.
Positive labeling was considered if at least one immunoparticle
was over the membrane or within ∼30 nm of it. Image-J (FIJI)
(NIH, USA; RRID: SCR_003070) was used to measure the
membrane length. Sampling was carefully and accurately carried
out in the sameway for all the animals studied, and experimenters
were blinded to the subject during CB1R quantification.
Synaptic terminals were identified by ultrastructural features.
Thus, asymmetric excitatory synapses showed typical presynaptic
terminals containing abundant clear and spherical synaptic
vesicles, and thick postsynaptic densities mostly on dendritic
spines. Inhibitory synapses had presynaptic terminals with
pleomorphic synaptic vesicles forming symmetric contacts with
postsynaptic dendrites. Astrocytes were identified by GFAP
immunoreaction product inside their cell bodies and processes.
The analysis was done over 1,910 synapses, 4,574 mitochondria
and 549 astrocytic profiles in TRPV1−/−; 2,177 synapses, 5,565
mitochondria and 413 astrocytic profiles in WT.
Image-J (FIJI) (NIH, USA; RRID: SCR_003070) was used
to measure the following parameters: percentage of CB1R-
positive terminals, mitochondria, and astrocytic profiles; density
of CB1R particles in terminal and astrocytic membranes
(particles/µm membrane); terminal perimeter; number of
terminals, mitochondria and astrocytic profiles; and proportion
of CB1R particles in each compartment vs. total CB1R labeling.
All values were shown as mean ± S.E.M. using a statistical
software package (GraphPad Prism 5; GraphPad Software; RRID:
SCR_002798). The normality test (Kolmogorov-Smirnov) was
always applied before running statistical tests. Sample uniformity
was assessed by one-way ANOVA or Kruskal-Wallis multiple
comparison test. Data from each group (n= 3) were pooled since
no significant differences were detected among mice (p > 0.05).
Finally, data were analyzed by parametric and non-parametric
tests (Unpaired t-test or Man-Whitney test). Values of p < 0.05
were considered statistically significant.
Whole Hippocampal Homogenates
Mice were deeply anesthetized by inhalation of isoflurane (2–4%)
before decapitation. Hippocampi from both hemispheres were
dissected andmanually homogenized with a plastic stick in a lysis
buffer composed of 10mM PB (pH 7.4), 5mM ethyleneglycol-
bis (2-aminoethylether)- N,N,N′,N′ tetraacetic acid, 5mM
ethylene-diamine-tetra-acetic acid, 1mM dithiotreitol, and
a protease inhibitor cocktail (Ref. P-8340, Sigma-Aldrich).
Thereafter, samples were kept 30min on ice and centrifuged
for 15min at 16,000 g. The resulting supernatant was used as
soluble protein extract. Protein concentrations were estimated
using Bio-Rad Protein Assay reagent (Ref. 500-0006, Bio-Rad
Laboratories SA).
Hippocampal Membrane Preparation
Hippocampal sections from TRPV1−/− and WT were thawed
in ice-cold 20mM Tris-HCl, pH 7.4, containing 1mM EGTA
(Tris/EGTA buffer), and then homogenized in 20 times
the volume of the same hypotonic buffer using a glass
homogenizer. Cell debris was discarded by centrifugation at
1,000 g (10min, 4◦C) and then membranes were obtained by
centrifugation at 40,000 g (30min, 4◦C). Finally, the pellet was
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re-suspended and re-centrifuged under the same conditions.
Membranes were aliquoted in microcentrifuge tubes, centrifuged
again (40,000 g, 30min, 4◦C) and the pellets were stored
at −75◦C prior to use. Protein content was determined
using the Bio-Rad dye reagent with bovine γ-globulin as
a standard.
Protein Determination
Hippocampal extracts from TRPV1−/− and WT were boiled
in urea-denaturing buffer [20mM Tris-HCl, pH 8.0, 12%
glycerol, 12% urea, 5% dithiothreitol, 2% sodium dodecyl
sulfate (SDS), 0.01% bromophenol blue] for 5min. Increasing
amounts of denatured proteins were resolved by electrophoresis
on SDS–polyacrylamide (SDS–PAGE) gels (10%) using the
Mini Protean II gel apparatus (Bio-Rad, Hercules, CA, USA).
Proteins were transferred to polyvinylidene fluoride (PVDF)
membranes (Amersham Bioscience, Buckinghamshire, UK)
using the Mini TransBlot transfer unit (Bio-Rad, Hercules,
CA, USA) at 90V constant voltage for 1 h at 4◦C. Blots were
blocked in 5% non-fat dry milk/PBS containing 0.5% BSA
and 0.2% Tween for 1 h, and incubated overnight at 4◦C with
specific antibodies against CB1R (0.2µg/ml; Frontier Science
Co., rabbit polyclonal; CB1-Rb-Af380; RRID: AB_2571591),
MAGL (0.2µg/ml; Frontier Science Co., rabbit polyclonal;
MGL-Rb-Af200; RRID: AB_2571798), DAGL (0.2µg/ml;
Frontier Science Co., rabbit polyclonal; DGLa-Rb-Af380;
RRID: AB_2571691), NAPE-PLD (0.2µg/ml; Frontier Science
Co., guinea pig polyclonal; NAPE-PLD-Gp-Af720; RRID:
AB_2571806), FAAH (0.2µg/ml; Cayman Chemical, rabbit
polyclonal; 101600-1; RRID: AB_327842), and CRIP1a (0.4
ng/µl; Santa Cruz Biotechnology, rabbit polyclonal; sc-137401;
RRID: AB_10709018). Blots were washed and incubated with
horseradish peroxidase (HRP) conjugated secondary antibodies;
goat anti-rabbit IgG HRP (1 ng/ml; Cell Signaling Technology;
7074; RRID: AB_2099233) and goat anti-guinea pig IgG HRP
(1 ng/ml; Bioss; bs-0358G; RRID: AB_10860553) diluted to
1:10,000 in blocking buffer for 2 h at RT. After the enhanced
chemiluminiscence detection (Santa Cruz) in an Autochemi-
UVP Bioimaging System, bands were quantified with Image-J
(FIJI) (NIH, USA; RRID: SCR_003070).
Western Blotting of Hippocampal
Synaptosomes
Hippocampal synaptosomes were prepared as previously
described (Garro et al., 2001). TRPV1−/− and WT mice
were anesthetized with isoflurane and decapitated; brains
were removed and placed on ice-cold 0.32M sucrose, pH 7.4,
containing 80mM Na2HPO4 and 20mM NaH2PO4 (sucrose
phosphate buffer) with protease inhibitors (Iodoacetamide
50µM, PMSF 1mM). The hippocampal tissue was minced
and homogenized in 10 volumes of sucrose/phosphate buffer
using a motor-driven Potter Teflon glass homogenizer (motor
speed 800 rpm; 10 up and down strokes; mortar cooled in
an ice-water mixture throughout). The homogenate was
centrifuged at 1,000 × g for 10min and obtained pellet (P1)
was re-suspended and pelleted. The supernatants (S1 + S1’)
were pelleted at 15,000 × g (P2) and re-suspended in the
homogenization buffer to a final volume of 16ml. This P2
fraction is a mixture of myelin fragments, synaptosomes and free
mitochondria. The suspension was layered directly onto tubes
containing 8ml 1.2M sucrose phosphate buffer, and centrifuged
at 180,000 × g for 20min. The material retained at the gradient
interface (synaptosome + myelin + microsome) was carefully
collected with a Pasteur-pipette and diluted with ice-cold
0.32M sucrose/phosphate buffer to a final volume of 16ml.
The diluted suspension was then layered onto 8ml of 0.8M
sucrose phosphate buffer, and centrifuged as described above.
The obtained pellet was re-suspended in ice-cold phosphate
buffer, pH 7.5 and aliquoted in microcentrifuge tubes. Aliquots
were then centrifuged at 40,000 × g for 30min, the supernatants
were aspirated and the pellets corresponding to the nerve
terminal membranes were stored at −80◦C. Protein content
was determined using the Bio-Rad dye reagent with bovine
γ-globulin as standard.
For western blotting, hippocampal synaptosome fractions
were boiled in urea-denaturing buffer [20mM Tris-HCl, pH
8.0, 12% glycerol, 12% Urea, 5% dithiothreitol, 2% sodium
dodecyl sulfate (SDS), 0.01% bromophenol blue] for 5min.
Denaturized proteins were resolved by electrophoresis on
SDS–polyacrylamide (SDS-PAGE) gels and transferred to
nitrocellulose or PVDF membranes at 30V constant voltage
overnight at 4◦C. Blots were blocked in 5% non-fat dry
milk/phosphate buffered saline containing 0.5% BSA and
0.1% Tween for 1 h, and incubated with the antibodies
overnight at 4◦C. Blots were washed and incubated with
specific HRP conjugated secondary antibodies diluted in
blocking buffer for 1.5 h at RT. Immunoreactive bands were
incubated with the ECL system according to the manufacturer
instructions. In these experiments, differences between the
relative expressions of proteins were analyzed by regression
line slopes comparison method by a statistical software





The patterns of CB1R and the main enzymes for synthesis
and degradation of 2-AG and AEA were studied in TRPV1−/−
(Figure 1). An increase in MAGL, FAAH, and NAPE-PLD, and
a slight decrease in DAGLα immunoreactivity was observed in
TRPV1−/− vs.WT. ThoughMAGL and FAAH immunostainings
were faint in both TRPV1−/− and WT hippocampus, MAGL
immunoreactivity increased more than FAAH and NAPE-PLD,
especially in the hilus and CA3 stratum lucidum. Noticeably,
CB1R staining increased overall TRPV1
−/− hippocampus, but
particularly stronger was in CA3 stratum radiatum, CA1
pyramidal cell layer and dentate ML. In the latter, CB1R
immunoreactivity was more intense in a fiber meshwork in the
inner 1/3 of the layer and weaker but yet more conspicuous
than in WT, in fibrous profiles distributed in the outer
2/3ML (Figure 1).
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FIGURE 1 | Immunoperoxidase method for light microscopy. Expression patterns of CB1R and endocannabinoid enzymes in WT and TRPV1
−/− mice hippocampi.
MAGL, NAPE-PLD, and FAAH immunoreactivity increases and DAGLα decreases in TRPV1−/−. CB1R immunoreactivity increases overall TRPV1
−/− hippocampus.
Scale bars: 500µm.
Expression of ECS Proteins in Whole
Hippocampal Homogenates and
Synaptosomes of TRPV1−/− Hippocampus
The expression of CB1R, DAGLα, FAAH, and MAGL was
investigated in whole homogenate extracts obtained from
TRPV1−/− and WT hippocampi (Figure 2A). The ∼27.5%
increase observed for CB1R in TRPV1
−/− was not statistically
significant (127.5 ± 23.83% vs. control 100%; p = 0.301 ns; n
= 8; Figure 2B). However, FAAH significantly increased (∼56%)
(156.3 ± 23.52 vs. control 100%; p = 0.0467∗, n = 8; Figure 2B)
and strikingly did MAGL in TRPV1−/− (∼288%) relative to
WT (388.1 ± 54.7% vs. control 100%; p = 0.0001∗∗∗, n =
8; Figure 2B). DAGLα remained unchanged (109.5 ± 7.5% vs.
control 100%; p= 0.2476 ns; n= 2; Figure 2B).
The CB1R compartmentalization was studied in homogenates
purified to P2 fractions (Figure 2C). Again, receptor expression
did not vary significantly between TRPV1−/− and WT (96.18
± 16.38% vs. control 100%; p = 0.8213 ns; Figure 2D).
However, synaptosomal fractions extracted from TRPV1−/−
homogenates (Figure 2E) revealed a significant ∼45% decrease
in CB1R (3.21 ± 0.82; WT: 5.87 ± 0.50; p = 0.0092
∗∗;
Figure 2F) and ∼42% decrease in MAGL (3.76 ± 1.16; WT:
6.51 ± 1.38; p = 0.0431∗; Figure 2F). The reduction was not
significant for NAPE-PLD (TRPV1−/−: 3.49 ± 1.26; WT: 4.83
± 0.80; p = 0.4186 ns; Figure 2F). In contrast, a significant
increase in CRIP1a was detected in TRPV1−/− (18.41 ± 1.89;
WT: 8.48 ± 1.32; p = 0.0006∗∗∗; Figure 2F). Finally, the
expression of DAGLα (TRPV1−/−: 5.72 ± 0.20; WT: 6.49 ±
0.5544; p = 0.31 ns; Figure 2F) and FAAH did not change in
TRPV1−/− (TRPV1−/−: 5.97 ± 0.32; WT: 6.41 ± 0.72; p =
0.607 ns; Figure 2F).
Cellular and Subcellular Localization of
CB1R in the Outer 2/3 Dentate ML of
TRPV1−/−
First, we confirmed the specificity of the antibody used
in this study as CB1R labeling was absent in the dentate
ML of CB1R-KO mice (Figure 3). CB1R immunoparticles
were localized to excitatory and inhibitory axon terminals,
astrocytes, and mitochondria (Figure 4). The proportion of
CB1R positive excitatory terminals increased in TRPV1
−/−
(31.71 ± 1.44%; WT: 28.03 ± 1.33%; p = 0.0103∗; Figure 5A)
but the receptor density remained unchanged (0.62 ± 0.015
particles/µm; WT: 0.63 ± 0.015 particles/µm; p = 0.2772 ns;
Figure 5B). Moreover, less excitatory terminals were observed
in TRPV1−/− (3.73 ± 0.115; WT: 4.33 ± 0.123 per 20 µm2,
p = 0.0003∗∗∗; Figure 5C) but were of larger size (1.89 ±
0.022µm, WT 1.80 ± 0.002µm; p = 0.0044∗∗; Figure 5D).
However, the number of CB1R positive excitatory terminals
(1.20 ± 0.057; WT: 1.14 ± 0.052 per 20 µm2; p = 0.4078
ns; Figure 5E) and their perimeter (2.08 ± 0.042µm; WT:
2.008 ± 0.043µm; p = 0.1431 ns; Figure 5F), were maintained
in TRPV1−/−.
There were not significant differences in the percentage of
CB1R positive inhibitory terminals (81 ± 2.70%; WT: 85.79
± 2.39%; p = 0.1594 ns; Figure 5A), number of inhibitory
terminals (0.91 ± 0.059; WT: 0.85 ± 0.052 per 20 µm2;
p = 0.7525 ns; Figure 5C), terminal perimeter (2.18 ± 0.055;
WT: 2.16 ± 0.071µm; p = 0.846 ns; Figure 5D), number of
CB1R positive inhibitory terminals (0.75 ± 0.055; WT: 0.74
± 0.049 per 20 µm2; p = 0.8098 ns; Figure 5E) or their
terminal perimeter (2.22 ± 0.063µm; WT 2.17 ± 0.079µm;
p = 0.1288 ns; Figure 5F). However, CB1R particle density
significantly decreased in TRPV1−/− inhibitory terminals (6.01
± 0.214 particles/µm; WT: 6.63 ± 0.199 particles/µm; p =
0.0402∗; Figure 5B).
There were no differences in the proportion of CB1R positive
mitochondria between TRPV1−/− (7.63± 0.40%) and WT (7.68
± 0.37%; p = 0.8748 ns; Figure 5A). However, the number of
mitochondria in TRPV1−/− (18.22 ± 0.37 per 20 µm2) was
significantly lower than in WT (23.24 ± 0.50 per 20 µm2; p <
0.0001∗∗∗∗; Figure 5C).
No significant changes were detected neither in the proportion
of CB1R positive astrocytic profiles in TRPV1
−/− (20.19 ±
3.31%) vs. WT (19.1 ± 3.29%; p = 0.39 ns; Figure 5A) nor in
the number of astrocytic profiles (TRPV1−/−: 1.27 ± 0.22 µm2;
WT: 0.98 ± 0.12 µm2 per 20 µm2; p = 0.2688 ns; Figure 5C).
In contrast, a significant decrease in CB1R density was observed
in TRPV1−/− astrocytes (0.24 ± 0.04 particles/µm; WT: 0.41 ±
0.072 particles/µm; p = 0.0452∗; Figure 5B). Lastly, a reduction
in the proportion of CB1R particles in inhibitory terminals
(TRPV1−/−: 61.02 ± 2.65% WT: 69.34 ± 5.28%; p = 0.2581 ns)
and dendrites (TRPV1−/−: 5.02 ± 1.11%; WT: 10.03 ± 1.75%;
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FIGURE 2 | (A,B) Immunoblot and relative expression of CB1R and endocannabinoid enzymes in hippocampal whole homogenates from WT and TRPV1
−/− mice.
MAGL and FAAH increase significantly in TRPV1−/−. Data were analyzed by means of non-parametric or parametric tests (Mann–Whitney U-test or Student’s t-test).
(C) Immunoblot of CB1R in whole homogenates and P2 extracts of raw membranes from WT and TRPV1
−/− mice hippocampi. (D) Relative expression of CB1R in P2
extracts from WT and TRPV1−/−. Not significant changes are detected in TRPV1−/−. Student’s t-test. (E,F) Immunoblot and relative expression of CB1R,
endocannabinoid enzymes, and CB1R interacting protein 1a in hippocampal synaptosomes from WT and TRPV1
−/− mice. CB1R and MAGL decrease but CRIP1a
increases significantly in TRPV1−/−. Fisher’s exact test. p > 0.05; p < 0.05*; p <0.005**; p< 0.001***. Data are expressed as mean ± S.E.M.
p = 0.0287∗) and, conversely, an increase in excitatory terminals
(TRPV1−/−: 16.41 ± 2.25%; WT: 9.84 ± 2.28%; p = 0.0573 ns)
and astrocytes (TRPV1−/−: 5.05 ± 0.87%; WT: 4.41 ± 0.73%; p
= 0.5856) was observed in TRPV1−/− (Figure 5G). Also, particle
distribution changed in TRPV1−/− (Figure 5H), as the number
of CB1R particles moderately dropped in inhibitory terminals
(∼21%) but drastically increased in excitatory terminals (∼63%).
Interestingly, the total number of CB1R particles significantly
increased in TRPV1−/− outer 2/3ML (TRPV1−/−: 42.1 ± 2.06
particles vs. 34.7 ± 1.55 particles WT per 20 µm2; ∗∗p = 0.0066;
Figure 5I), but the number of membrane particles was not seen
to change (TRPV1−/−: 25.07 ± 2.06 particles; WT: 26.81 ± 7.4
particles per 20 µm2; p > 0.05; Figure 5J).
Cellular and Subcellular Localization of
CB1R in the Inner 1/3 Dentate ML of
TRPV1−/−
CB1R immunoparticles were found in excitatory and inhibitory
terminals, astrocytes andmitochondria (Figure 6). In TRPV1−/−
was observed a significant increase in the proportion of CB1R
positive excitatory terminals (45.48± 2.33%;WT: 35.19± 2.20%;
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FIGURE 3 | Specificity of the CB1R antibodies in dentate ML of the CB1R-KO mouse processed for electron microscopy. (A,C) Single pre-embedding immunogold
method for CB1R. (B,D) Double pre-embedding immunogold for CB1R and immunoperoxidase for GFAP method. No CB1R labeling is detected in the outer 2/3 (A,B)
and inner 1/3 of the layer (C,D). Scale bars: 0.5µm.
p = 0.0004∗∗∗; Figure 7A) with no changes in CB1R density
(0.60 ± 0.019 particles/µm; WT: 0.67 ± 0.025 particles/µm;
p = 0.0635 ns; Figure 7B), and a reduction in the number of
excitatory terminals (3.16 ± 0.13; WT: 3.67 ± 0.16 terminals
per 20 µm2; p = 0.034∗; Figure 7C). Moreover, the perimeter of
excitatory terminals increased in TRPV1−/− (2.09 ± 0.042µm;
WT: 1.91± 0.035µm; p= 0.0014∗∗; Figure 7D), but the number
of CB1R positive excitatory terminals (TRPV1
−/−: 1.47 ± 0.09;
WT: 1.56 ± 0.247 per 20 µm2; p = 0.3029 ns; Figure 7E)
and their perimeter (2.26 ± 0.077µm; WT: 2.08 ± 0.068µm;
p = 0.0951 ns; Figure 7F) were not significant different between
TRPV1−/− and WT.
There were no changes in TRPV1−/− in the percentage of
CB1R positive inhibitory terminals (82.43 ± 4.13%; WT: 82.18
± 3.714%; p = 0.8141 ns; Figure 7A), CB1R density (5.88 ±
0.37 particles/µm; WT: 7.05 ± 0.35 particles/µm; p = 0.0578
ns; Figure 7B), number of inhibitory terminals (0.67 ± 0.063
terminal; WT: 0.87 ± 0.075 terminal per 20 µm2; p = 0.0892
ns; Figure 7C), their perimeter (2.58 ± 0.101µm; WT: 2.45
± 0.096µm; p = 0.2392 ns; Figure 7D), number of CB1R
positive inhibitory terminals (0.56 ± 0.059 terminal; WT: 0.75
± 0.073 terminal per 20 µm2; p = 0.0917 ns; Figure 7E) and
their perimeter (2.63 ± 0.113µm; WT: 2.51 ± 0.115µm; p =
0.3863 ns; Figure 7F).
The overall percentage of CB1R positive mitochondria (10.35
± 0.71%; WT: 11.06 ± 0.73%; p = 0.4208 ns; Figure 7A) and
the number of mitochondria (17.22 ± 0.48; WT: 16.74 ± 0.43
per 20 µm2; p = 0.33 ns; Figure 7C) were similar between
TRPV1−/− and WT.
Also, the proportion of CB1R positive astrocytic profiles
(28.95 ± 2.67%; WT: 32.53 ± 3.23%; p = 0.39 ns; Figure 7A),
CB1R density (0.39 ± 0.047 particles/µm; WT: 0.34 ± 0.029
particles/µm; p = 0.4245 ns; Figure 7B) and the number
of astrocytic profiles (1.93 ± 0.072 µm2; WT: 1.93 ±
0.082 µm2 per 20 µm2; p = 0.9123 ns; Figure 7C) did
not vary between TRPV1−/− and WT. However, the CB1R
particle distribution seen in WT changed in TRPV1−/−
(Figure 7H). Thus, a significant reduction was observed in
TRPV1−/−in the proportion CB1R particles at inhibitory
terminals (TRPV1−/−: 41.11 ± 3.41%; WT: 63.73 ± 3.24%;
p < 0.0001∗∗∗∗), while there was an increase at excitatory
terminals (TRPV1−/−: 11.28 ± 1.61%; 19.07 ± 1.51%; p
= 0.0014∗∗), neuronal mitochondria (TRPV1−/−: 10.76 ±
1.32%; WT: 56.16 ± 0.53%; p = 0.0281∗) and dendrites
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FIGURE 4 | CB1R localization in the outer 2/3ML of WT and TRPV1
−/− mice. Pre-embedding immunogold method for electron microscopy. CB1R immunoparticles
(arrows) are localized to inhibitory terminals (ter, red arrows, red shading), excitatory terminals (ter, green arrows, green shading), and mitochondrial outer membranes
(m, purple arrows, purple shading) in WT (A,C) and TRPV1−/− (B,D). CB1R particles are also on membranes of GFAP positive astrocytic processes (as, yellow
arrows, yellow shading) in WT (E) and TRPV1−/− (F). Combined pre-embedding immunoperoxidase and immunogold method. sp, dendritic spine; den, dendrite;
Scale bars: 0.5µm.
(TRPV1−/−: 9.23 ± 1.14%; WT: 3.92 ± 0.78%; p = 0.0017∗∗)
(Figure 7G). Moreover, a significant decrease in the number
of CB1R particles was found in inhibitory terminals (∼53%)
and an increase in excitatory terminals (∼50%) in TRPV1−/−
(Figure 7H). Finally, a significant increase in the total number
of CB1R particles was found in TRPV1
−/− inner 1/3ML
(49.63 ± 3.39 particles; WT: 42.04 ± 1.87 particles per
20 µm2; ∗p = 0.0475; Figure 7I), while the number of
membrane particles decreased significantly in TRPV1−/− vs.
WT (TRPV1−/−: 16.95 ± 1.37 particles; WT: 27.35 ± 2.64
particles; ∗∗∗p = 0.0002; Figure 7J). The total amount of CB1R
labeling was similar among the WT mice used (Figures 8A,C).
Likewise, labeling was comparable among the TRPV1−/− mice
(Figures 8B,D).
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FIGURE 5 | Statistical assessment of CB1R labeling in several subcellular compartments in the outer 2/3ML of WT and TRPV1
−/− mice. (A) Percentage of CB1R
positive excitatory and inhibitory terminals, mitochondria, and astrocytes. (B) Density of CB1R (particles/µm). (C) Number of excitatory and inhibitory terminals,
(Continued)
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FIGURE 5 | mitochondria, and astrocytes in 20 µm2. (D) Perimeter (µm) of synaptic terminals. (E) Number of CB1R positive excitatory and inhibitory terminals,
mitochondria, and astrocytes in 20 µm2. (F) Perimeter (µm) of CB1R positive synaptic terminals. Data were analyzed by non-parametric or parametric tests
(Mann–Whitney U-test or Student’s t-test). (G) Proportion of CB1R labeling in excitatory and inhibitory terminals, astrocytes, mitochondria (neuronal, astroglial), and
dendrites normalized to the total CB1R content. (H) Number of CB1R particles in the compartments analyzed in (G). Chi square test. (I) Total number of CB1R
particles in 20 µm2. (J) Number of CB1R particles found in membranes in 20 µm
2. Mann–Whitney U-test or Student’s t-test. p < 0.05*; p < 0.01**; p < 0.001***; p <
0.0001****. All data are represented as mean ± S.E.M.
DISCUSSION
The main finding of this study was that the constitutive deletion
of the TRPV1 gene impacts on the expression and localization of
some elements of the ECS. Thus, the increase in CB1R, FAAH,
MAGL and NAPE-PLD immunoreactivity in the TRPV1−/−
hippocampus indicates the existence of compensatory changes.
However, CB1R did not change significantly and only FAAH
and MAGL increased when measured in western blots of
whole hippocampal homogenates. Certainly, this is a powerful
technique to detect low protein levels (Garro et al., 2001), but
subtle changes in protein expression can be better achieved by
homogenate fractioning into P2 extracts and raw synaptosomes
(Garro et al., 2001). Thus, MAGL increased in whole TRPV1−/−
hippocampal homogenates, but a significant MAGL decrease
with no changes in FAAH stood out in TRPV1−/− synaptosomes.
One plausible explanation for this discrepancy would be that
MAGL expression in astrocytes (Uchigashima et al., 2011)
increases in the absence of TRPV1, but decreases the MAGL
pool localized in presynaptic terminals (Gulyas et al., 2004;
Uchigashima et al., 2011). Finally, 2-AG dysregulation would
be expected to occur in TRPV1−/− as DAGLα expression did
not change in the absence of TRPV1. FAAH mostly localizes
to intracellular organelle membranes but is also on somatic
and dendritic membranes (Gulyas et al., 2004), while NAPE-
PLD is very highly localized in hippocampal granule cell
axons (Egertová et al., 2008). Hence, the FAAH increase in
whole homogenates with no obvious changes in NAPE-PLD
in TRPV1−/− synaptosomes would drop AEA in TRPV1−/−.
However, NAPE-PLD immunoreactivity increased in the dentate
hilar region and CA3 stratum lucidum, indicating that AEA
might be augmented in certain subcellular compartments, e.g.,
granule cell axons.
Interestingly, CB1R expression did not suffer any variation
in P2 fractions from TRPV1−/− but significantly decreased in
synaptosomal extracts. To circumvent the limiting factors of
raw synaptosomes unable to discriminate between presynaptic
and postsynaptic compartments, we investigated the CB1R
localization in TRPV1−/− by high resolution immunoelectron
microscopy. We focused on the dentate ML because its outer
2/3 correspond to the termination zone of the glutamatergic
entorhino-dentate pathway (Grandes and Streit, 1991) which
transmits spatial information through the medial perforant path
(Fyhn et al., 2004) and non-spatial information via the lateral
perforant path (Burwell, 2000). The inner 1/3ML receives the
glutamatergic mossy cell commissural/associational axons which
innervate the dentate granule cells involved in the signaling
of environmental and context information (Scharfman and
Myers, 2012). Our anatomical data confirmed the biochemical
results. Thus, similar changes were found in the inner 1/3
and outer 2/3ML but with slight differences, that might be
reflecting that distinct TRPV1 expression patterns trigger specific
compensatory effects. For instance, the relative increase in
CB1R positive excitatory terminals in TRPV1
−/− was more
pronounced in the inner 1/3 than outer 2/3ML. However, taking
into account that the CB1R density in excitatory terminals
did not change throughout the entire ML, the reduction in
the number of CB1R negative excitatory terminals might likely
be explaining the increase seen in CB1R positive excitatory
terminals. Thus, TRPV1 deletion modifies unevenly the total
number of excitatory terminals boosting the proportion of
excitatory terminals equipped with CB1R, which is in line with
the reduced glutamatergic innervation observed in TRPV1−/−
hippocampus (Hurtado-Zavala et al., 2017). We observed in
TRPV1−/− a decrease in the proportion of CB1R particles
located in inhibitory terminals in both the inner 1/3 (34.5% ↓)
and outer 2/3ML (15.5% ↓) as well as an increase in CB1R
labeling in excitatory terminals in the inner 1/3 (83.80% ↑) and
outer 2/3 (73.50% ↑) (see below). Furthermore, considering the
total number of CB1R particles counted, the particles localized
in inhibitory terminals decreased ∼53% in the inner 1/3 and
∼21% in the outer 2/3ML in TRPV1−/−. Nevertheless, the
differences in inhibitory terminals in TRPV1−/− relative to WT
were minimal because only a small reduction in CB1R density
was found to be significant in the outer 2/3ML. Bearing in mind
that the majority of CB1R particles are localized to GABAergic
terminals in the hippocampus (Kano et al., 2009; Gutiérrez-
Rodríguez et al., 2017, 2018; Bonilla-Del Río et al., 2019), it would
be plausible that an impairment in receptor renewal could be
more pronounced in inhibitory than excitatory terminals and
therefore easier to be detected. This would also lead to guess that
if the overall CB1R expression at excitatory terminals remains
unchanged, the decrease in CB1R density at inhibitory terminals
could indeed be responsible for the CB1R fall in synaptosomal
fractions. Actually, the CRIP1a increase observed in TRPV1−/−
might also be playing role as its overexpression interferes with
CB1R activity and receptor downregulation (Smith et al., 2015).
About 75% of the total TRPV1 positive granule cell dendritic
spines and 56% of the dendrites were in the outer 2/3, and
the rest in the inner 1/3ML (Puente et al., 2015). Furthermore,
about 30% of the inhibitory synapses in the inner 1/3ML have
TRPV1 mostly localized to postsynaptic dendritic membranes
(Canduela et al., 2015). In the absence of TRPV1, CB1R may
exert a major regulatory effect on the excitatory transmission
with important functional consequences in the dentate ML. In
this sense, we have recently shown that CB1R immunolabeling
decreases by 34% in excitatory terminals and the proportion
of CB1R immunopositive excitatory boutons decreases by 35%
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FIGURE 6 | CB1R localization in the inner 1/3ML of WT and TRPV1
−/− mice. Pre-embedding immunogold method for electron microscopy. CB1R immunoparticles
(arrows) are localized to inhibitory terminals (ter, red arrows, red shading), excitatory terminals (ter, green arrows, green shading), and mitochondrial outer membranes
(m, purple arrows, purple shading) in WT (A,C) and TRPV1−/− (B,D). CB1R particles are also on membranes of GFAP positive astrocytic processes (as, yellow
arrows, yellow shading) in WT (E) and TRPV1−/− (F). Combined pre-embedding immunoperoxidase and immunogold method. sp, dendritic spine; den, dendrite; GC,
granule cell. Scale bars: 0.5µm.
in the middle 1/3ML of the adult mouse subjected to ethanol
intake during adolescence (binge drinking model). These deficits
in glutamatergic CB1Rs were associated with the loss of eCB-
eLTD at the MPP-granule cell synapses and an impairment of
recognition memory (Peñasco et al., 2020). TRPV1 changes upon
the loss or absence of CB1R remain to be investigated.
CB1Rs are also in mitochondria where they regulate cellular
respiration, energy production, and memory formation in the
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FIGURE 7 | Statistical assessment of CB1R labeling in several subcellular compartments in the inner 1/3ML of WT and TRPV1
−/− mice. (A) Percentage of CB1R
positive excitatory and inhibitory terminals, mitochondria and astrocytes. (B) Density of CB1R (particles/µm). (C) Number of excitatory and inhibitory terminals,
(Continued)
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FIGURE 7 | mitochondria and astrocytes in 20 µm2. (D) Perimeter (µm) of synaptic terminals. (E) Number of CB1R positive excitatory and inhibitory terminals,
mitochondria and astrocytes in 20 µm2. (F) Perimeter (µm) of CB1R positive synaptic terminals. Data were analyzed by non-parametric or parametric tests
(Mann–Whitney U-test or Student’s t-test). (G) Proportion of CB1R labeling in excitatory and inhibitory terminals, astrocytes, mitochondria (neuronal, astroglial), and
dendrites normalized to the total CB1R content. (H) Number of CB1R particles in the compartments analyzed in (G). Chi square test. (I) Total number of CB1R
particles in 20 µm2. (J) Number of CB1R particles found in membranes in 20 µm
2. Mann–Whitney U-test or Student’s t-test. p < 0.05*; p < 0.01**; p < 0.001***; p <
0.0001****. All data are represented as mean ± S.E.M.
FIGURE 8 | Assessment of sample uniformity in CB1R labeling in the outer 2/3 and inner 1/3ML of WT and TRPV1
−/− mice. (A,C) The total number of CB1R
particles per 20 µm2 was similar in the 3 WT mice (p < 0.05; Kruskal-Wallis test). (B,D) The same applied for the 3 TRPV1−/− mice (p < 0.05; Kruskal-Wallis).
hippocampus (Hebert-Chatelain et al., 2016). The proportion of
mitochondrial CB1R in TRPV1
−/− was maintained regardless
TRPV1 is expressed in mitochondrial membranes (Miyake et al.,
2015). However, despite that the number of mitochondrial
profiles was kept in the inner 1/3ML, a significant reduction was
observed in the outer 2/3ML, suggesting that TRPV1 could have
a direct implication in mitochondrial dynamics. The differences
observed between both ML zones may be due to differences
in their neuronal composition and distinct effects of TRPV1
absence. Thus, strong TRPV1-mediated mitochondrial calcium-
influx causes cytotoxicity and cell death in HEK 293 cells and
dorsal root ganglion neurons (Stueber et al., 2017), while TRPV1
knockdown improves mitochondrial function and apoptosis
inhibition in primary cardiomyocytes (Sun et al., 2014).
The CB1R is also localized to astrocytes (Navarrete and
Araque, 2010; Metna-Laurent and Marsicano, 2015; Gutiérrez-
Rodríguez et al., 2017). Calcium rise linked to TRPV1
activation drives cytoskeletal rearrangements, microtubule
disassembly, and filament reorganization leading to astrocyte
migration (Goswami et al., 2007; Morales-Lázaro et al.,
2013). However, TRPV1 antagonism has an opposite effect
(Ho et al., 2014). We did not detect differences in astrocytic
parameters in TRPV1−/−, thus astrocytic disturbance does
not seem to happen in the absence of TRPV1. TRPV1
deletion could have triggered compensatory mechanisms
in other receptors/channels that would replace its function.
Furthermore, there were not changes in the proportion of
CB1R positive astrocytic profiles in TRPV1
−/− ML. However,
a significant reduction in CB1R density in astrocytes was
observed in TRPV1−/− outer 2/3ML resembling the CB1R
density decrease in astrocytes revealed in a binge-drinking
model of ethanol intake (Bonilla-Del Río et al., 2019). Astrocytes
participate in inflammatory responses through the release
of pro-inflammatory molecules (Farina et al., 2007) that
can be soothing by astroglial CB1R-mediated mechanisms
(Metna-Laurent and Marsicano, 2015). Hence, because of
the reduced CB1R density in astrocytes, it is reasonable to
expect an impairment of an anti-inflammatory response in
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TRPV1−/−. Furthermore, the decrease in astrocytic CB1R
density could also have functional consequences in synaptic
transmission and plasticity, as astrocytes may not be effective in
detecting the endocannabinoids produced on demand by neural
activity, compromising gliotransmitter availability elicited by
cannabinoids at the synapses (Araque et al., 2014).
Altogether, the lack of TRPV1 causes changes in the ECS
that might be affecting synaptic transmission and plasticity, and
eventually behavior.
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